Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Centogene N.V. (CNTGF)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: CNTGF (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $0
1 Year Target Price $0
| 0 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -60.62% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 4.26M USD | Price to earnings Ratio - | 1Y Target Price 1.5 |
Price to earnings Ratio - | 1Y Target Price 1.5 | ||
Volume (30-day avg) - | Beta -0.12 | 52 Weeks Range 0.04 - 0.55 | Updated Date 06/16/2025 |
52 Weeks Range 0.04 - 0.55 | Updated Date 06/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.46 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -73.21% | Operating Margin (TTM) -63.29% |
Management Effectiveness
Return on Assets (TTM) -26.76% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 76368227 | Price to Sales(TTM) 0.09 |
Enterprise Value 76368227 | Price to Sales(TTM) 0.09 | ||
Enterprise Value to Revenue 1.36 | Enterprise Value to EBITDA -1.58 | Shares Outstanding 29000100 | Shares Floating 12252558 |
Shares Outstanding 29000100 | Shares Floating 12252558 | ||
Percent Insiders 4.57 | Percent Institutions 59.37 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Centogene N.V.
Company Overview
History and Background
Centogene N.V. was founded in 2006 in Rostock, Germany. It specializes in rare disease genetics, offering diagnostic testing and pharmaceutical development services. The company went public in 2019.
Core Business Areas
- Diagnostics: Genetic testing and diagnostic services for rare diseases, including whole genome sequencing, exome sequencing, and targeted gene panels.
- Pharmaceutical: Partnerships with pharmaceutical companies for drug development and clinical trial support in rare diseases.
- Data: Offers access to a rare disease database for research and development purposes.
Leadership and Structure
The CEO of Centogene N.V. is Kim Stratton. The organizational structure includes departments for diagnostics, pharmaceutical, and data services.
Top Products and Market Share
Key Offerings
- Whole Genome Sequencing (WGS): Comprehensive genetic testing service used to identify genetic variants associated with rare diseases. Market share data is unavailable, but competitors include Illumina and Thermo Fisher Scientific. High revenue from this segment.
- CENTOGENE Biodatabank: A comprehensive repository of clinical and genetic data on rare disease patients, used for research and development. Market share data is not publicly available. Competitors are other biobanks and data providers like WuXi NextCODE.
- Newborn Screening: Testing newborns for a panel of genetic disorders to enable early intervention. Market share data is unavailable. Competitors include PerkinElmer and Eurofins.
Market Dynamics
Industry Overview
The rare disease diagnostics and therapeutics market is growing, driven by advancements in genomics and increased awareness of rare diseases. Increased regulation and funding for rare disease research are also contributing to growth.
Positioning
Centogene N.V. is positioned as a key player in rare disease diagnostics and data, with a focus on providing comprehensive genetic testing and biobanking services. Its competitive advantage lies in its expertise in rare disease genetics and its proprietary database.
Total Addressable Market (TAM)
The global rare disease diagnostics and therapeutics market is expected to reach hundreds of billions of dollars. Centogene is positioned to capitalize on this TAM through its comprehensive genetic testing, data access and partnering with pharmaceutical companies.
Upturn SWOT Analysis
Strengths
- Expertise in rare disease genetics
- Proprietary rare disease database
- Global reach
- Partnerships with pharmaceutical companies
Weaknesses
- Reliance on partnerships
- Competition in the diagnostics market
- Cash Burn
Opportunities
- Expanding into new geographic markets
- Developing new diagnostic tests
- Increasing collaborations with pharmaceutical companies
- Expansion of Biodatabank database through more patient data
Threats
- Competition from larger diagnostics companies
- Changes in reimbursement policies
- Data privacy regulations
- Economic Downturn
Competitors and Market Share
Key Competitors
- ILMN
- TMO
- LH
Competitive Landscape
Centogene N.V. faces competition from larger diagnostics companies. It differentiates itself through its focus on rare diseases and its proprietary database. They are much smaller than their competitors.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is available in company reports.
Future Projections: Future growth projections are available from analyst reports.
Recent Initiatives: Recent initiatives include expanding partnerships with pharmaceutical companies and launching new diagnostic tests.
Summary
Centogene N.V. is a specialized company in rare disease genetics with a valuable bio databank. Their partnerships with pharmaceutical companies provides solid income. They face intense competition from larger diagnostic companies. Further expansion depends on new test development and geographical penetration.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Yahoo Finance
- Google Finance
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market share data is approximate. Financial data should be verified with the latest company reports.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Centogene N.V.
Exchange NASDAQ | Headquaters - | ||
IPO Launch date - | CEO - | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 384 | Website https://www.centogene.com |
Full time employees 384 | Website https://www.centogene.com | ||
Centogene N.V., together with its subsidiaries, provides pharmaceutical solutions and diagnostic tests in Europe, the Middle East, North America, Latin America, and the Asia Pacific. The company offers data-driven answers to patients, physicians, and pharmaceutical companies for rare and neurodegenerative diseases. It provides CENTOGENE MOx 2.0, a single-step multiomic solution that combines DNA sequencing, biochemical testing, and RNA sequencing; CentoCloud, a cloud-based Software as a Service platform, which enables laboratories to analyze, interpret, and report genomic variants for rare disease diagnostics; FilterTool, a web-based application for genetic data interpretation; and NEW CentoGenome, a Next Generation Sequencing (NGS)-based assay that provides diagnostic information to accelerate access to potential treatment options. The company also offers target and drug screening, clinical development, and market access and expansion, as well as CENTOGENE Biodatabank licenses and insight reports. In addition, it provides early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services, such as whole exome sequencing, whole genome sequencing, and multiomic testing solutions to physicians, laboratories, and hospitals directly or through distributors. The company was founded in 2006 and is headquartered in Rostock, Germany.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.